Abstract | BACKGROUND: Despite the benefits of antimigraine medications for patients with migraines, parenteral administration of these drugs has certain disadvantages for at-home patient use. OBJECTIVE: DESIGN: Double-blind, placebo-controlled trial in patients with migraines. SETTING: Both private and institutional practice. PATIENTS: A total of 348 patients with a diagnosis of migraine according to International Headache Society criteria were recruited; 310 patients qualified for participation. INTERVENTIONS: MAIN OUTCOME MEASURES: Patients rated pain severity, functional ability, headache pain relief, incidence and severity of nausea, and the incidence of vomiting, photophobia, and phonophobia prior to treatment (base-line) and again at 0.5, 1, 2, 3, and 4 hours after treatment. Recurrences of headache pain within 24 hours were also noted. RESULTS: CONCLUSIONS:
|
Authors | R M Gallagher |
Journal | Archives of neurology
(Arch Neurol)
Vol. 53
Issue 12
Pg. 1285-91
(Dec 1996)
ISSN: 0003-9942 [Print] United States |
PMID | 8970458
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Placebos
- Dihydroergotamine
|
Topics |
- Acute Disease
- Administration, Intranasal
- Adolescent
- Adult
- Aged
- Dihydroergotamine
(administration & dosage)
- Double-Blind Method
- Female
- Hallucinations
(drug therapy, etiology)
- Humans
- Male
- Middle Aged
- Migraine Disorders
(complications, drug therapy)
- Nausea
(drug therapy, etiology)
- Placebos
- Self Administration
|